SK59393A3 - Use of il-4 to enhance immune response to immunogegens in vaccines - Google Patents

Use of il-4 to enhance immune response to immunogegens in vaccines Download PDF

Info

Publication number
SK59393A3
SK59393A3 SK593-93A SK59393A SK59393A3 SK 59393 A3 SK59393 A3 SK 59393A3 SK 59393 A SK59393 A SK 59393A SK 59393 A3 SK59393 A3 SK 59393A3
Authority
SK
Slovakia
Prior art keywords
vaccine
mammal
immune response
administered
pharmaceutical composition
Prior art date
Application number
SK593-93A
Other languages
English (en)
Slovak (sk)
Inventor
Edward J Rozhon
John F O'connell
Stuart A Cox
Michael D Hayre
Jerome Schwartz
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of SK59393A3 publication Critical patent/SK59393A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Peptides Or Proteins (AREA)
SK593-93A 1990-12-19 1991-12-17 Use of il-4 to enhance immune response to immunogegens in vaccines SK59393A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62980090A 1990-12-19 1990-12-19
PCT/US1991/009167 WO1992011030A1 (en) 1990-12-19 1991-12-17 Use of il-4 to enhance immune response to immunogens in vaccines

Publications (1)

Publication Number Publication Date
SK59393A3 true SK59393A3 (en) 1994-03-09

Family

ID=24524543

Family Applications (1)

Application Number Title Priority Date Filing Date
SK593-93A SK59393A3 (en) 1990-12-19 1991-12-17 Use of il-4 to enhance immune response to immunogegens in vaccines

Country Status (20)

Country Link
EP (1) EP0563254B1 (de)
JP (1) JPH06503830A (de)
CN (1) CN1063227A (de)
AT (1) ATE129900T1 (de)
AU (1) AU9161591A (de)
CA (1) CA2098726A1 (de)
CZ (1) CZ119993A3 (de)
DE (1) DE69114519T2 (de)
DK (1) DK0563254T3 (de)
ES (1) ES2079851T3 (de)
FI (1) FI932759A (de)
GR (1) GR3018820T3 (de)
HU (1) HUT68529A (de)
IE (1) IE70453B1 (de)
IL (1) IL100402A0 (de)
OA (1) OA09863A (de)
PT (1) PT99838A (de)
SK (1) SK59393A3 (de)
WO (1) WO1992011030A1 (de)
ZA (1) ZA919907B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5268454A (en) 1991-02-08 1993-12-07 La Jolla Pharmaceutical Company Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier
US7449186B1 (en) 1990-08-02 2008-11-11 Fred Hutchinson Cancer Research Center Methods of blocking the interaction between stromal cells and hemopoietic cells with anti-VCAM-1 antibodies
US5827670A (en) * 1990-08-02 1998-10-27 Fred Hutchinson Cancer Research Center Methods of isolating and detecting bone marrow stromal cells with VCAM-1-specific antibodies
US5206345A (en) * 1990-08-02 1993-04-27 Fred Hutchinson Cancer Research Center Il-4 and tnf induce mab 6g10-recognized expression on bone marrow stromal cells
WO1994003202A1 (en) * 1992-08-10 1994-02-17 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Interleukin-4 stimulated t lymphocyte cell death
AU7101294A (en) * 1993-06-07 1995-01-03 Endocon, Inc. Implant stimulated cellular immunity
HUT76101A (en) * 1994-04-08 1997-06-30 Brigham & Womens Hospital Treatment of autoimmune disease using oral tolerization and/or th2-enhancing cytokines
US6660258B1 (en) 1997-05-09 2003-12-09 Pharma Pacific Pty Ltd Oromucosal cytokine compositions and uses thereof
FR2769505B1 (fr) * 1997-10-10 2000-06-30 Michael Gerard Tovey Compositions de cytokines a administrer a la muqueuse buccale, et leurs utilisations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT83761B (pt) * 1985-11-19 1989-06-30 Schering Biotech Corp Metodo para a producao de interleuquina-4 de mamifero
EP0275300B1 (de) * 1986-08-01 1996-01-03 Commonwealth Scientific And Industrial Research Organisation Rekombinanter impfstoff
JP3485184B2 (ja) * 1989-07-14 2004-01-13 アメリカン サイアナミド カンパニー インターロイキン含有安定ワクチン組成物
ATE133074T1 (de) * 1990-03-21 1996-02-15 Schering Corp Verwendung von il-4 zur verstärkung der immunantwort auf infektiöse antigen- herausforderungen

Also Published As

Publication number Publication date
ATE129900T1 (de) 1995-11-15
EP0563254B1 (de) 1995-11-08
FI932759A0 (fi) 1993-06-16
OA09863A (en) 1994-08-15
FI932759A (fi) 1993-06-16
CN1063227A (zh) 1992-08-05
CA2098726A1 (en) 1992-06-20
DE69114519D1 (de) 1995-12-14
ES2079851T3 (es) 1996-01-16
ZA919907B (en) 1992-08-26
JPH06503830A (ja) 1994-04-28
AU9161591A (en) 1992-07-22
DE69114519T2 (de) 1996-04-04
EP0563254A1 (de) 1993-10-06
CZ119993A3 (en) 1994-02-16
DK0563254T3 (da) 1996-02-12
IE70453B1 (en) 1996-11-27
IE914436A1 (en) 1992-07-01
GR3018820T3 (en) 1996-04-30
PT99838A (pt) 1992-12-31
HU9301797D0 (en) 1993-10-28
WO1992011030A1 (en) 1992-07-09
IL100402A0 (en) 1992-09-06
HUT68529A (en) 1995-06-28

Similar Documents

Publication Publication Date Title
Daynes et al. Induction of common mucosal immunity by hormonally immunomodulated peripheral immunization
JP3485184B2 (ja) インターロイキン含有安定ワクチン組成物
CA2153794A1 (en) Vaccine compositions and method for induction of mucosal immune response via systemic vaccination
US8632781B2 (en) Immunogenic compounds comprising peptides of IL1β
CA1297003C (en) Composition and method for treating animals
US5866134A (en) Method for enhancing the antibody response to specific antigens with Interleukin-10
Villacres-Eriksson et al. IMMUNOMODULATION BYQUILLAJA SAPONARIAADJUVANT FORMULATIONS: IN VIVO STIMULATION OF INTERLEUKIN 12 AND ITS EFFECTS ON THE ANTIBODY RESPONSE
SK59393A3 (en) Use of il-4 to enhance immune response to immunogegens in vaccines
CA2372181A1 (en) Adjuvant combination formulations
Hayglass et al. Antigen-specific inhibition of ongoing murine IgE responses. II. Inhibition of IgE responses induced by treatment with glutaraldehyde-modified allergens is paralleled by reciprocal increases in IgG2a synthesis.
JP2002526420A (ja) 脊椎動物における実質的に無毒で生物学的に活性な粘膜アジュバント
Audibert et al. Enhancement by murabutide of the immune response to natural and synthetic hepatitis B surface antigens
JPH07504662A (ja) 免疫無防備状態の宿主における治療用途のための免疫促進剤
US6063380A (en) Enhanced immunogenic vaccine
EP0351876A2 (de) Zusammensetzung zur Steigerung der Impfungswirkung
NZ250555A (en) Vaccine with enhanced immunogenicity by inclusion of a cytokine
US6355256B1 (en) Compositions containing a p53 derived protein or peptide, an adjuvant, and interleukin-12 and uses thereof
Allison Antigens and adjuvants for a new generation of vaccines
AU1876595A (en) Prolactin as a vaccine adjuvant
Chedid Use of Muramyl Peptides in Synthetic and Semisynthetic Vaccines
US20080299073A1 (en) Method For Treatment Or Prophylaxis Of An Infection Using Either An Antibody Which Binds To IL-9 Or An Agent Which Stimulates Production Of Autoantibodies To Interleukin-9
JP2001521908A (ja) ワクチンアジュバントとして有用な封入された免疫調節物質
García et al. Factors that influence the immunogenicity of human recombinant interferon alpha-2b in mice
JP2000154148A (ja) インターフェロンβをアジュバントとするワクチン
MXPA97007295A (en) Method for improving antibody response to specific antigens with interleucine